Form 4: Neurocrine Biosciences Director Shalini Sharp Reports Stock Transactions
SEC Form 4 Filing
Director Shalini Sharp reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.
Summary
- On May 22, 2025, Director Shalini Sharp reported transactions involving Neurocrine Biosciences Inc. (NBIX) securities.
- Sharp acquired 1,659 Restricted Stock Units (RSUs) on May 21, 2025, which will vest fully on May 21, 2026.
- Sharp also acquired 3,305 Non-Qualified Stock Options on May 21, 2025, exercisable in monthly installments starting June 21, 2025, and expiring on May 21, 2035.
- Additionally, 1,435 shares of common stock were disposed of on May 22, 2025.
- Following these transactions, Sharp directly owns 0 shares of common stock, 1,659 RSUs, and 3,305 Non-Qualified Stock Options.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency into insider activity.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders can use this information to understand the trading activity of a key insider.
- The transactions themselves may have a minor impact on the stock price, but the disclosure provides transparency.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of earliest transaction; acquisition of RSUs and stock options. |
| 05/21/2026 | RSUs will vest in full. |
| 06/21/2025 | Options vest in 12 monthly installments beginning this date. |
| 05/21/2035 | Expiration date of the stock options. |
| 05/22/2025 | Date of Form 4 filing; disposal of common stock. |
Keywords
Form 4, Neurocrine Biosciences, NBIX, Director, Shalini Sharp, Stock Options, Restricted Stock Units, Securities, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.